This guide explains selected U.S. federal compounding rules. It is consumer information, not legal or medical advice. We have not audited any seller's licensure or determined whether a particular prescription complies with the law. Read our medical disclaimer and site funding disclosure.
Compounded semaglutide can qualify for exemptions from certain federal drug requirements only when the applicable conditions are met. A prescription, pharmacy licence or claim of personalization does not, by itself, establish that every condition has been satisfied. The relevant questions concern the formulation, the patient's needs and the rules applying to the compounder.
Compounding does not confer FDA approval
Compounded medicines do not undergo FDA's premarket approval review for safety, effectiveness and quality. They are also distinct from FDA-approved generic drugs. Compounding can address a medical need that an approved medicine cannot meet, but poor preparation can cause contamination or an incorrect amount of active ingredient. See FDA's compounding questions and answers.
503A and 503B have different requirements
- Section 503A: covers qualifying compounding by licensed pharmacists in state-licensed pharmacies or federal facilities, and by licensed physicians. It generally concerns an identified patient and a prescription, with limited anticipatory compounding allowed under specified conditions.
- Section 503B: covers registered outsourcing facilities. Their drugs are subject to current good manufacturing practice requirements, and FDA primarily oversees these facilities. Outsourcing facilities can supply health care practitioners without first obtaining an individual patient's prescription.
State boards generally oversee traditional pharmacies day to day; FDA can also inspect them. Facility registration does not approve its compounded products. These are selected distinctions, not a complete compliance checklist. Sources: FDA's oversight overview and 503A guidance, pages 2–3 (PDF).
A lower price does not establish a patient-specific difference
Section 503A restricts regular or excessive compounding of products that are essentially copies of commercially available drugs. Under FDA's guidance, the assessment considers active ingredients, strength and route of administration. A prescriber can determine that a formulation change produces a significant difference for an identified patient; FDA expects that determination to be documented.
FDA explicitly says a lower price does not establish this difference. A patient's name and formulation alone are also insufficient documentation. See FDA's 503A guidance, pages 5–9 (PDF).
Adding another ingredient is not an automatic exception. FDA's April 1, 2026 clarification explains that semaglutide combined with vitamin B12 may still meet its copy criteria. The individual facts matter.
The shortage history needs dates
FDA declared the tirzepatide injection shortage resolved on December 19, 2024, and the semaglutide injection shortage resolved on February 21, 2025. Its policy page describes subsequent transition periods and court-related updates; those historical periods should not be presented as continuing permission.
In its April 1, 2026 update, FDA states that semaglutide and tirzepatide appear on neither its shortage list nor its 503B bulks list. For outsourcing facilities using bulk ingredients, FDA describes a separate requirement: the ingredient must be on the 503B clinical-need list, or the resulting drug must be in shortage at compounding, distribution and dispensing. A 503A patient-specific explanation does not remove that separate 503B requirement.
We checked this FDA policy timeline on September 13, 2026. Follow its link to the current shortage database when assessing a later date.
Warnings FDA identifies
- Semaglutide salts: FDA identifies semaglutide sodium and acetate as different active ingredients from the approved products and says it knows of no lawful basis for their use in compounding.
- Retatrutide and cagrilintide: FDA's consumer guidance states that these cannot be compounded under federal law.
- Misleading labels: FDA has identified products naming nonexistent pharmacies or real pharmacies that did not make them.
These statements are attributed to FDA's unapproved GLP-1 guidance, checked September 13, 2026. They do not establish the circumstances of any individual seller.
Research labels do not establish suitability for treatment
The same FDA guidance warns against products sold directly for human use while labelled for research or not for human consumption. FDA says their quality is unknown and they may be harmful. Such wording does not demonstrate approval or clinical suitability.
Questions for your clinician or pharmacist
Use these questions to clarify your care, not to certify a seller yourself:
- What is the exact formulation, and is it an approved product or a compounded preparation?
- If compounding is proposed, what medical need cannot be met by an approved medicine?
- Who will compound and dispense it, and which regulatory framework applies?
- If a patient-specific formulation change is the basis, what difference has the prescriber identified and documented?
- Who can explain the label, storage requirements and administration instructions, and answer follow-up questions?
- Where can concerns about the pharmacy or the product be reported?
FDA's state pharmacy licence directory links official lookup services. Its checks also include a prescription requirement, a U.S. physical address and telephone number, and access to a licensed pharmacist. A listing is a verification step; it does not determine every product's legal status.
What our editorial reviews can establish
Reading public policies can identify what a company discloses. It cannot establish that a particular prescription, batch, facility or shipment complies with all applicable requirements. We have removed the earlier aggregate seller claims from this legal explainer because they were not a regulatory audit. Our review method describes the scope of our editorial work.
Applying this to your situation
Ask your treating clinician about medical suitability and your pharmacist about the specific preparation. Questions about a seller's compliance or legal exposure require the relevant regulator or a qualified lawyer. This page does not determine anyone's criminal or civil liability.
Sources and correction note
Editorial correction — September 13, 2026: clarified the separate 503A and 503B rules, added dated shortage-policy context, and removed blanket legal assurances, older seller-count claims and repeated provider purchasing recommendations. The questions above replace the earlier checklist, which inconsistently described its number of steps.
Primary FDA sources are linked beside each explanation. This is a selective federal overview, not an exhaustive review of statutes, state law, litigation or enforcement actions. Guidance documents describe FDA's interpretation and policies; they are not themselves a complete statement of binding law. Provider prices and commercial terms were not rechecked for this correction.